Share Price and Basic Stock Data
Last Updated: January 14, 2026, 8:17 pm
| PEG Ratio | -12.91 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Zydus Wellness Ltd operates in the food processing sector, focusing on bakery, dairy, fruits, and other products. The company reported a market capitalization of ₹14,023 Cr and a stock price of ₹441. Over the past few years, Zydus has demonstrated a consistent upward trend in sales, with reported figures of ₹2,009 Cr for FY 2022, rising to ₹2,255 Cr in FY 2023, and further increasing to ₹2,328 Cr in FY 2024. The trailing twelve months (TTM) sales reached ₹2,886 Cr, indicating robust growth. Quarterly sales figures reflect some fluctuations, with a peak of ₹913 Cr projected for March 2025, suggesting strong seasonal demand. The company’s operating profit margins (OPM) have varied significantly, reflecting challenges in cost management, particularly with margins standing at 4% for the latest quarter, down from a high of 20% in March 2023. This volatility highlights the need for strategic initiatives to stabilize revenue streams and improve profitability.
Profitability and Efficiency Metrics
Zydus Wellness has reported a net profit of ₹253 Cr for the TTM, translating to an earnings per share (EPS) of ₹7.96. The company’s profitability metrics indicate a return on equity (ROE) of 6.02% and a return on capital employed (ROCE) of 6.16%, both of which are on the lower end compared to industry averages. The interest coverage ratio (ICR) stands at a strong 32.77x, indicating that Zydus comfortably meets its interest obligations. However, the operating profit margin has been subject to significant fluctuations, ranging from 3% to 21% over recent quarters. This inconsistency suggests potential inefficiencies in cost management and pricing strategies. The cash conversion cycle (CCC) of 75 days indicates a moderate efficiency in managing receivables and inventory, which can be improved to enhance working capital utilization.
Balance Sheet Strength and Financial Ratios
Zydus Wellness’s balance sheet reflects a total debt of ₹3,042 Cr against reserves of ₹5,642 Cr, indicating a manageable debt-to-equity ratio of 0.03. The company has maintained a current ratio of 1.48, suggesting adequate liquidity to cover short-term liabilities. The book value per share stood at ₹891.76 as of March 2025, reinforcing the company’s solid equity position. However, the total liabilities increased to ₹9,882 Cr by September 2025, indicating a growing leverage that may warrant caution. The price-to-book value (P/BV) ratio is at 1.87x, suggesting that the stock is trading at a premium compared to its net asset value, which may limit upside potential for investors. The company’s strategic management of its capital structure will be crucial in maintaining financial stability amid rising borrowings and fluctuating profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Zydus Wellness indicates a strong promoter holding of 69.64%, which reflects significant insider confidence in the company’s long-term prospects. Foreign institutional investors (FIIs) hold 3.43%, while domestic institutional investors (DIIs) account for 18.76% of the equity. The public shareholding stands at 8.18%, with a total of 77,188 shareholders as of September 2025. The gradual increase in promoter shareholding from 65.36% in December 2022 to 69.64% indicates a trend of confidence among insiders, while the slight decline in DII participation may signal caution among institutional investors regarding the stock’s volatility. The stability of this shareholding structure is critical for maintaining investor confidence and ensuring long-term growth and operational stability.
Outlook, Risks, and Final Insight
Looking ahead, Zydus Wellness faces both opportunities and challenges. The company’s growth trajectory in sales and a strong balance sheet position it well for future expansion. However, the volatility in profit margins and fluctuating operating performance poses risks that could affect investor sentiment. The potential for improving operational efficiency and managing costs effectively remains a significant area for enhancement. Additionally, market competition and changing consumer preferences in the food processing sector could impact future growth. As Zydus navigates these dynamics, its ability to stabilize margins and leverage its solid capital base will be key to sustaining investor confidence and achieving long-term success. Overall, while Zydus Wellness has strengths in its financial structure and market presence, it must address its profitability challenges to fully capitalize on growth opportunities in the sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mishtann Foods Ltd | 498 Cr. | 4.62 | 7.79/4.28 | 1.49 | 10.9 | 0.00 % | 42.2 % | 44.1 % | 1.00 |
| Mrs Bectors Food Specialities Ltd | 7,093 Cr. | 232 | 355/224 | 52.1 | 39.6 | 0.52 % | 18.1 % | 15.6 % | 2.00 |
| Nakoda Group of Industries Ltd | 50.2 Cr. | 28.6 | 44.0/22.2 | 18.8 | 0.00 % | 8.11 % | 15.4 % | 10.0 | |
| HMA Agro Industries Ltd | 1,378 Cr. | 27.5 | 40.4/26.8 | 11.1 | 17.3 | 1.13 % | 11.8 % | 11.5 % | 1.00 |
| Himalaya Food International Ltd | 81.2 Cr. | 9.57 | 17.9/8.95 | 14.1 | 21.8 | 0.00 % | 2.29 % | 2.79 % | 10.0 |
| Industry Average | 21,752.19 Cr | 653.33 | 131.53 | 89.69 | 0.27% | 16.37% | 17.51% | 5.63 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 429 | 416 | 713 | 702 | 440 | 403 | 783 | 841 | 493 | 462 | 913 | 861 | 650 |
| Expenses | 413 | 388 | 568 | 586 | 423 | 390 | 620 | 686 | 473 | 447 | 723 | 705 | 628 |
| Operating Profit | 16 | 28 | 145 | 116 | 17 | 13 | 162 | 155 | 20 | 15 | 190 | 156 | 23 |
| OPM % | 4% | 7% | 20% | 17% | 4% | 3% | 21% | 18% | 4% | 3% | 21% | 18% | 4% |
| Other Income | 1 | 1 | -6 | -12 | 4 | 3 | 4 | 5 | 10 | 4 | 1 | 3 | -33 |
| Interest | 3 | 4 | 5 | 5 | 6 | 6 | 6 | 4 | 1 | 3 | 4 | 2 | 16 |
| Depreciation | 6 | 6 | 7 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 13 | 11 | 25 |
| Profit before tax | 8 | 19 | 126 | 93 | 9 | 4 | 154 | 152 | 24 | 10 | 173 | 145 | -51 |
| Tax % | -4% | -1% | -15% | -18% | 31% | 92% | 3% | 3% | 12% | 37% | 1% | 12% | 4% |
| Net Profit | 8 | 20 | 145 | 110 | 6 | 0 | 150 | 148 | 21 | 6 | 172 | 128 | -53 |
| EPS in Rs | 0.27 | 0.62 | 4.57 | 3.47 | 0.19 | 0.01 | 4.72 | 4.64 | 0.66 | 0.20 | 5.40 | 4.02 | -1.66 |
Last Updated: January 2, 2026, 4:41 pm
Below is a detailed analysis of the quarterly data for Zydus Wellness Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 650.00 Cr.. The value appears to be declining and may need further review. It has decreased from 861.00 Cr. (Jun 2025) to 650.00 Cr., marking a decrease of 211.00 Cr..
- For Expenses, as of Sep 2025, the value is 628.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 705.00 Cr. (Jun 2025) to 628.00 Cr., marking a decrease of 77.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Jun 2025) to 23.00 Cr., marking a decrease of 133.00 Cr..
- For OPM %, as of Sep 2025, the value is 4.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Jun 2025) to 4.00%, marking a decrease of 14.00%.
- For Other Income, as of Sep 2025, the value is -33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Jun 2025) to -33.00 Cr., marking a decrease of 36.00 Cr..
- For Interest, as of Sep 2025, the value is 16.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Jun 2025) to 16.00 Cr., marking an increase of 14.00 Cr..
- For Depreciation, as of Sep 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.00 Cr. (Jun 2025) to 25.00 Cr., marking an increase of 14.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -51.00 Cr.. The value appears to be declining and may need further review. It has decreased from 145.00 Cr. (Jun 2025) to -51.00 Cr., marking a decrease of 196.00 Cr..
- For Tax %, as of Sep 2025, the value is 4.00%. The value appears to be improving (decreasing) as expected. It has decreased from 12.00% (Jun 2025) to 4.00%, marking a decrease of 8.00%.
- For Net Profit, as of Sep 2025, the value is -53.00 Cr.. The value appears to be declining and may need further review. It has decreased from 128.00 Cr. (Jun 2025) to -53.00 Cr., marking a decrease of 181.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -1.66. The value appears to be declining and may need further review. It has decreased from 4.02 (Jun 2025) to -1.66, marking a decrease of 5.68.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:44 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 404 | 431 | 397 | 431 | 513 | 843 | 1,767 | 1,867 | 2,009 | 2,255 | 2,328 | 2,709 | 2,886 |
| Expenses | 319 | 331 | 305 | 331 | 387 | 658 | 1,446 | 1,522 | 1,664 | 1,918 | 2,020 | 2,329 | 2,503 |
| Operating Profit | 85 | 100 | 91 | 99 | 125 | 185 | 321 | 344 | 345 | 337 | 308 | 380 | 383 |
| OPM % | 21% | 23% | 23% | 23% | 24% | 22% | 18% | 18% | 17% | 15% | 13% | 14% | 13% |
| Other Income | 19 | 28 | 32 | 32 | 35 | 28 | -33 | -123 | 10 | -5 | -0 | 19 | -25 |
| Interest | 0 | 0 | 0 | 1 | 2 | 30 | 140 | 84 | 26 | 16 | 24 | 12 | 26 |
| Depreciation | 0 | 8 | 7 | 7 | 9 | 13 | 26 | 25 | 24 | 25 | 24 | 28 | 54 |
| Profit before tax | 104 | 120 | 117 | 124 | 150 | 171 | 121 | 112 | 306 | 291 | 260 | 359 | 278 |
| Tax % | 5% | 7% | 10% | 10% | 9% | -0% | -17% | -6% | -1% | -7% | -3% | 3% | |
| Net Profit | 98 | 111 | 105 | 111 | 137 | 171 | 142 | 119 | 309 | 310 | 267 | 347 | 253 |
| EPS in Rs | 4.94 | 5.58 | 5.28 | 5.58 | 6.85 | 5.87 | 4.92 | 3.73 | 9.71 | 9.75 | 8.39 | 10.90 | 7.96 |
| Dividend Payout % | 24% | 22% | 25% | 23% | 23% | 17% | 20% | 27% | 10% | 10% | 12% | 11% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.27% | -5.41% | 5.71% | 23.42% | 24.82% | -16.96% | -16.20% | 159.66% | 0.32% | -13.87% | 29.96% |
| Change in YoY Net Profit Growth (%) | 0.00% | -18.67% | 11.12% | 17.71% | 1.39% | -41.78% | 0.76% | 175.86% | -159.34% | -14.19% | 43.83% |
Zydus Wellness Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 9% |
| 3 Years: | 10% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 13% |
| 3 Years: | 2% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 9% |
| 3 Years: | 14% |
| 1 Year: | 7% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 6% |
| Last Year: | 6% |
Last Updated: September 4, 2025, 9:45 pm
Balance Sheet
Last Updated: December 4, 2025, 12:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 39 | 39 | 39 | 39 | 58 | 58 | 64 | 64 | 64 | 64 | 64 | 64 |
| Reserves | 286 | 367 | 439 | 518 | 652 | 3,329 | 3,403 | 4,504 | 4,780 | 5,059 | 5,294 | 5,608 | 5,642 |
| Borrowings | 0 | 0 | 0 | 25 | 25 | 1,569 | 1,519 | 550 | 387 | 297 | 329 | 188 | 3,042 |
| Other Liabilities | 99 | 102 | 89 | 100 | 112 | 503 | 610 | 548 | 461 | 413 | 462 | 582 | 1,134 |
| Total Liabilities | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 | 9,882 |
| Fixed Assets | 95 | 84 | 82 | 103 | 104 | 4,567 | 4,674 | 4,667 | 4,710 | 4,732 | 4,708 | 5,125 | 8,446 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 10 | 4 | 4 | 12 | 13 | 10 | 15 | 13 |
| Investments | 5 | 0 | 94 | 30 | 148 | 46 | 110 | 0 | 27 | 70 | 78 | 36 | 28 |
| Other Assets | 324 | 423 | 391 | 550 | 577 | 835 | 802 | 995 | 943 | 1,018 | 1,354 | 1,266 | 1,394 |
| Total Assets | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,442 | 9,882 |
Below is a detailed analysis of the balance sheet data for Zydus Wellness Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 64.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 64.00 Cr..
- For Reserves, as of Sep 2025, the value is 5,642.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,608.00 Cr. (Mar 2025) to 5,642.00 Cr., marking an increase of 34.00 Cr..
- For Borrowings, as of Sep 2025, the value is 3,042.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 188.00 Cr. (Mar 2025) to 3,042.00 Cr., marking an increase of 2,854.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,134.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 582.00 Cr. (Mar 2025) to 1,134.00 Cr., marking an increase of 552.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 9,882.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,442.00 Cr. (Mar 2025) to 9,882.00 Cr., marking an increase of 3,440.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 8,446.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,125.00 Cr. (Mar 2025) to 8,446.00 Cr., marking an increase of 3,321.00 Cr..
- For CWIP, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 36.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 8.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,394.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,266.00 Cr. (Mar 2025) to 1,394.00 Cr., marking an increase of 128.00 Cr..
- For Total Assets, as of Sep 2025, the value is 9,882.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,442.00 Cr. (Mar 2025) to 9,882.00 Cr., marking an increase of 3,440.00 Cr..
Notably, the Reserves (5,642.00 Cr.) exceed the Borrowings (3,042.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 85.00 | 100.00 | 91.00 | 74.00 | 100.00 | 184.00 | 320.00 | -206.00 | -42.00 | 40.00 | -21.00 | 192.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 2 | 1 | 3 | 3 | 6 | 42 | 24 | 18 | 26 | 34 | 44 | 49 |
| Inventory Days | 108 | 76 | 73 | 127 | 113 | 393 | 168 | 158 | 135 | 146 | 150 | 148 |
| Days Payable | 191 | 146 | 191 | 264 | 254 | 662 | 289 | 189 | 136 | 100 | 116 | 122 |
| Cash Conversion Cycle | -82 | -69 | -116 | -134 | -135 | -227 | -97 | -13 | 25 | 80 | 78 | 75 |
| Working Capital Days | -48 | -37 | -38 | -57 | -26 | -26 | -7 | -35 | -27 | 17 | 20 | 34 |
| ROCE % | 35% | 32% | 26% | 23% | 22% | 7% | 6% | 6% | 6% | 6% | 5% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Parag Parikh Flexi Cap Fund | 22,000,000 | 0.73 | 946.99 | N/A | N/A | N/A |
| Nippon India Small Cap Fund | 16,848,030 | 1.06 | 725.22 | 2,221,106 | 2025-12-08 07:42:13 | 658.54% |
| Quant Small Cap Fund | 9,033,845 | 1.29 | 388.86 | N/A | N/A | N/A |
| Nippon India Consumption Fund | 1,358,672 | 2.1 | 58.48 | 1,403,000 | 2025-12-15 00:28:01 | -3.16% |
| Quant Multi Cap Fund | 1,250,000 | 0.61 | 53.81 | N/A | N/A | N/A |
| Parag Parikh ELSS Tax Saver Fund | 1,135,555 | 0.83 | 48.88 | N/A | N/A | N/A |
| Quant ESG Integration Strategy Fund | 426,074 | 6.72 | 18.34 | 432,771 | 2025-12-15 00:28:01 | -1.55% |
| Baroda BNP Paribas India Consumption Fund | 300,000 | 0.83 | 12.91 | N/A | N/A | N/A |
| Union Value Fund | 82,500 | 0.96 | 3.55 | N/A | N/A | N/A |
| Taurus ELSS Tax Saver Fund | 54,975 | 3.05 | 2.37 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 37.00 | 41.94 | 48.78 | 48.54 | 19.55 |
| Diluted EPS (Rs.) | 37.00 | 41.94 | 48.78 | 48.54 | 19.55 |
| Cash EPS (Rs.) | 59.01 | 45.71 | 52.71 | 52.25 | 22.61 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 891.76 | 842.37 | 805.07 | 761.28 | 717.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 891.76 | 842.37 | 805.07 | 761.28 | 717.87 |
| Revenue From Operations / Share (Rs.) | 425.93 | 366.01 | 354.36 | 315.75 | 293.36 |
| PBDIT / Share (Rs.) | 61.84 | 50.64 | 53.75 | 55.81 | 55.52 |
| PBIT / Share (Rs.) | 57.37 | 46.90 | 49.82 | 52.10 | 51.57 |
| PBT / Share (Rs.) | 56.41 | 40.90 | 45.71 | 48.09 | 17.63 |
| Net Profit / Share (Rs.) | 54.54 | 41.97 | 48.78 | 48.54 | 18.66 |
| NP After MI And SOA / Share (Rs.) | 54.54 | 41.97 | 48.78 | 48.54 | 18.66 |
| PBDIT Margin (%) | 14.51 | 13.83 | 15.16 | 17.67 | 18.92 |
| PBIT Margin (%) | 13.47 | 12.81 | 14.05 | 16.50 | 17.57 |
| PBT Margin (%) | 13.24 | 11.17 | 12.89 | 15.23 | 6.01 |
| Net Profit Margin (%) | 12.80 | 11.46 | 13.76 | 15.37 | 6.36 |
| NP After MI And SOA Margin (%) | 12.80 | 11.46 | 13.76 | 15.37 | 6.36 |
| Return on Networth / Equity (%) | 6.11 | 4.98 | 6.05 | 6.37 | 2.59 |
| Return on Capital Employeed (%) | 6.40 | 5.54 | 6.16 | 6.73 | 6.70 |
| Return On Assets (%) | 5.38 | 4.34 | 5.32 | 5.42 | 2.09 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 |
| Total Debt / Equity (X) | 0.03 | 0.06 | 0.05 | 0.07 | 0.12 |
| Asset Turnover Ratio (%) | 0.43 | 0.38 | 0.05 | 0.04 | 0.02 |
| Current Ratio (X) | 1.48 | 1.62 | 1.31 | 1.06 | 1.10 |
| Quick Ratio (X) | 0.78 | 1.02 | 0.65 | 0.58 | 0.62 |
| Inventory Turnover Ratio (X) | 5.50 | 2.24 | 0.89 | 0.78 | 0.54 |
| Dividend Payout Ratio (NP) (%) | 9.16 | 11.91 | 10.25 | 10.30 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 8.47 | 10.93 | 9.48 | 9.57 | 0.00 |
| Earning Retention Ratio (%) | 90.84 | 88.09 | 89.75 | 89.70 | 0.00 |
| Cash Earning Retention Ratio (%) | 91.53 | 89.07 | 90.52 | 90.43 | 0.00 |
| Interest Coverage Ratio (X) | 32.77 | 13.42 | 21.27 | 13.92 | 4.22 |
| Interest Coverage Ratio (Post Tax) (X) | 29.42 | 12.71 | 20.93 | 13.11 | 3.99 |
| Enterprise Value (Cr.) | 10742.16 | 9439.42 | 10116.33 | 9760.97 | 12849.96 |
| EV / Net Operating Revenue (X) | 3.97 | 4.05 | 4.49 | 4.86 | 6.88 |
| EV / EBITDA (X) | 27.31 | 29.31 | 29.58 | 27.48 | 36.37 |
| MarketCap / Net Operating Revenue (X) | 3.92 | 4.02 | 4.37 | 4.75 | 6.72 |
| Retention Ratios (%) | 90.83 | 88.08 | 89.74 | 89.69 | 0.00 |
| Price / BV (X) | 1.87 | 1.75 | 1.93 | 1.97 | 2.75 |
| Price / Net Operating Revenue (X) | 3.92 | 4.02 | 4.37 | 4.75 | 6.72 |
| EarningsYield | 0.03 | 0.02 | 0.03 | 0.03 | 0.01 |
After reviewing the key financial ratios for Zydus Wellness Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.00. This value is within the healthy range. It has decreased from 41.94 (Mar 24) to 37.00, marking a decrease of 4.94.
- For Diluted EPS (Rs.), as of Mar 25, the value is 37.00. This value is within the healthy range. It has decreased from 41.94 (Mar 24) to 37.00, marking a decrease of 4.94.
- For Cash EPS (Rs.), as of Mar 25, the value is 59.01. This value is within the healthy range. It has increased from 45.71 (Mar 24) to 59.01, marking an increase of 13.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 891.76. It has increased from 842.37 (Mar 24) to 891.76, marking an increase of 49.39.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 891.76. It has increased from 842.37 (Mar 24) to 891.76, marking an increase of 49.39.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 425.93. It has increased from 366.01 (Mar 24) to 425.93, marking an increase of 59.92.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 61.84. This value is within the healthy range. It has increased from 50.64 (Mar 24) to 61.84, marking an increase of 11.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 57.37. This value is within the healthy range. It has increased from 46.90 (Mar 24) to 57.37, marking an increase of 10.47.
- For PBT / Share (Rs.), as of Mar 25, the value is 56.41. This value is within the healthy range. It has increased from 40.90 (Mar 24) to 56.41, marking an increase of 15.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 54.54. This value is within the healthy range. It has increased from 41.97 (Mar 24) to 54.54, marking an increase of 12.57.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 54.54. This value is within the healthy range. It has increased from 41.97 (Mar 24) to 54.54, marking an increase of 12.57.
- For PBDIT Margin (%), as of Mar 25, the value is 14.51. This value is within the healthy range. It has increased from 13.83 (Mar 24) to 14.51, marking an increase of 0.68.
- For PBIT Margin (%), as of Mar 25, the value is 13.47. This value is within the healthy range. It has increased from 12.81 (Mar 24) to 13.47, marking an increase of 0.66.
- For PBT Margin (%), as of Mar 25, the value is 13.24. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 13.24, marking an increase of 2.07.
- For Net Profit Margin (%), as of Mar 25, the value is 12.80. This value exceeds the healthy maximum of 10. It has increased from 11.46 (Mar 24) to 12.80, marking an increase of 1.34.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.80. This value is within the healthy range. It has increased from 11.46 (Mar 24) to 12.80, marking an increase of 1.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.11. This value is below the healthy minimum of 15. It has increased from 4.98 (Mar 24) to 6.11, marking an increase of 1.13.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.40. This value is below the healthy minimum of 10. It has increased from 5.54 (Mar 24) to 6.40, marking an increase of 0.86.
- For Return On Assets (%), as of Mar 25, the value is 5.38. This value is within the healthy range. It has increased from 4.34 (Mar 24) to 5.38, marking an increase of 1.04.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.43. It has increased from 0.38 (Mar 24) to 0.43, marking an increase of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 1.5. It has decreased from 1.62 (Mar 24) to 1.48, marking a decrease of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 24) to 0.78, marking a decrease of 0.24.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.50. This value is within the healthy range. It has increased from 2.24 (Mar 24) to 5.50, marking an increase of 3.26.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.16. This value is below the healthy minimum of 20. It has decreased from 11.91 (Mar 24) to 9.16, marking a decrease of 2.75.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.47. This value is below the healthy minimum of 20. It has decreased from 10.93 (Mar 24) to 8.47, marking a decrease of 2.46.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.84. This value exceeds the healthy maximum of 70. It has increased from 88.09 (Mar 24) to 90.84, marking an increase of 2.75.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.53. This value exceeds the healthy maximum of 70. It has increased from 89.07 (Mar 24) to 91.53, marking an increase of 2.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 32.77. This value is within the healthy range. It has increased from 13.42 (Mar 24) to 32.77, marking an increase of 19.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 29.42. This value is within the healthy range. It has increased from 12.71 (Mar 24) to 29.42, marking an increase of 16.71.
- For Enterprise Value (Cr.), as of Mar 25, the value is 10,742.16. It has increased from 9,439.42 (Mar 24) to 10,742.16, marking an increase of 1,302.74.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.97. This value exceeds the healthy maximum of 3. It has decreased from 4.05 (Mar 24) to 3.97, marking a decrease of 0.08.
- For EV / EBITDA (X), as of Mar 25, the value is 27.31. This value exceeds the healthy maximum of 15. It has decreased from 29.31 (Mar 24) to 27.31, marking a decrease of 2.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has decreased from 4.02 (Mar 24) to 3.92, marking a decrease of 0.10.
- For Retention Ratios (%), as of Mar 25, the value is 90.83. This value exceeds the healthy maximum of 70. It has increased from 88.08 (Mar 24) to 90.83, marking an increase of 2.75.
- For Price / BV (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has increased from 1.75 (Mar 24) to 1.87, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has decreased from 4.02 (Mar 24) to 3.92, marking a decrease of 0.10.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Zydus Wellness Ltd:
- Net Profit Margin: 12.8%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.4% (Industry Average ROCE: 16.37%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.11% (Industry Average ROE: 17.51%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 29.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 50.3 (Industry average Stock P/E: 131.53)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.8%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Food Processing - Bakery/Dairy/Fruits/Others | Zydus Corporate Park, Ahmedabad Gujarat 382481 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Sharvil P Patel | Chairman |
| Mr. Tarun G Arora | WholeTime Director & CEO |
| Mr. Ganesh N Nayak | Non Executive Director |
| Mr. Kulin S Lalbhai | Independent Director |
| Mr. Akhil A Monappa | Independent Director |
| Mr. Srivishnu Raju Nandyala | Independent Director |
| Ms. Dharmishtaben N Raval | Independent Woman Director |
FAQ
What is the intrinsic value of Zydus Wellness Ltd?
Zydus Wellness Ltd's intrinsic value (as of 14 January 2026) is ₹434.79 which is 2.07% lower the current market price of ₹444.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹14,165 Cr. market cap, FY2025-2026 high/low of ₹531/299, reserves of ₹5,642 Cr, and liabilities of ₹9,882 Cr.
What is the Market Cap of Zydus Wellness Ltd?
The Market Cap of Zydus Wellness Ltd is 14,165 Cr..
What is the current Stock Price of Zydus Wellness Ltd as on 14 January 2026?
The current stock price of Zydus Wellness Ltd as on 14 January 2026 is ₹444.
What is the High / Low of Zydus Wellness Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Zydus Wellness Ltd stocks is ₹531/299.
What is the Stock P/E of Zydus Wellness Ltd?
The Stock P/E of Zydus Wellness Ltd is 50.3.
What is the Book Value of Zydus Wellness Ltd?
The Book Value of Zydus Wellness Ltd is 179.
What is the Dividend Yield of Zydus Wellness Ltd?
The Dividend Yield of Zydus Wellness Ltd is 0.27 %.
What is the ROCE of Zydus Wellness Ltd?
The ROCE of Zydus Wellness Ltd is 6.16 %.
What is the ROE of Zydus Wellness Ltd?
The ROE of Zydus Wellness Ltd is 6.02 %.
What is the Face Value of Zydus Wellness Ltd?
The Face Value of Zydus Wellness Ltd is 2.00.